Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Atrovent® Inhalation Solution

Study type: Observational

Funder types: Industry

Identifiers

NCT02238197

244.2500

Details and patient eligibility

About

To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

Enrollment: 477 patients

Sex: All

Ages: 13 to 89 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of both genders, older than 40 years,who suffer from chronic obstructive Pulmonary disease
• Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion

Exclusion criteria

• Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® 500µg/2ml Inhalation Solution
• Patients who exhibited adverse drug reactions

Trial design

477 participants in 1 patient group

Chronic Obstructive Pulmonary Disease

Treatment:

Drug: Atrovent® Inhalation Solution